Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma

Abstract Background Monoclonal antibodies targeting the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) (e.g., ipilimumab [IPI]) and the programmed cell death-1 (PD1) receptor (e.g., nivolumab [NIVO]) represent significant breakthroughs in the treatment of advanced melanoma. A combination of the...

Full description

Bibliographic Details
Main Authors: Ravi Potluri, Sandip Ranjan, Hitesh Bhandari, Helen Johnson, Andriy Moshyk, Srividya Kotapati
Format: Article
Language:English
Published: BMC 2019-07-01
Series:Experimental Hematology & Oncology
Subjects:
Advanced melanoma
Melanoma
Nivolumab
Ipilimumab
Healthcare cost comparison
CheckMate 067
Online Access:http://link.springer.com/article/10.1186/s40164-019-0138-9

Internet

http://link.springer.com/article/10.1186/s40164-019-0138-9

Similar Items